Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare disorder caused by inflammation and demyelination of the peripheral nerves characterized by weakness associated with loss of reflexes. Multiple approved immunoglobulins (IVIgs, SCIgs), low-cost generic off-label corticosteroids, and PLEX are available for the management of CIDP. However, there are ample opportunities for new players developing novel therapies, particularly targeting refractory patients—a sizeable patient pool—to address the need for effective therapies that are safe and provide long-term relief with chronic use. Given the high unmet need for better treatment alternatives that are effective over the long-term, physicians are likely to adopt these new therapies even if they provide modest benefit over the available treatment options. These brands can command premium pricing if they fulfill the need, particularly if they are effective in the treatment-refractory patient segment.
Questions answered
Product description
Executive Insights provides indication-specific market intelligence withworld-class epidemiology, keen insight into current treatment paradigms, biotherapeutic pipelines, key clinical unmet needs, and competitive landscapes, supported by primary and secondary research. This solution provides succinct insights to any biopharma function or business professional looking to quickly grasp a new indication of interest.
Geography
United States, EU5 (France, Germany, Italy, Spain United Kingdom).
Primary research
13 KOL interviews from November 2021 to January 2022.
Key company covered
CSL Behring, Grifols, Octapharma, Takeda, Argenx, Sanofi, Pfizer, Biotest, others.
Key drugs covered
Gamunex, Privigen, Panzyga, Gammaked, Octagam, Kiovig / Gammagard, Flebogamma, Hizentra, HyQvia, efgartigimod, and SAR445088.